Clinical Trial

Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to thoroughly explore and ascertain the mechanism of action of the therapy with the EXOMIND (BTL-699-2) device in the treatment of food cravings (serving as an important precipitant to binge eating episodes), among binge eaters and to confirm its efficacy and safety, in adult binge-eating patients with food cravings. The main question it aims to answer is: To ascertain the mechanism of action of the treatment with the EXOMIND (BTL-699-2) device equipped with a BTL-699-AP-M-2 applicator in reducing food cravings, for the active group only. Participants will complete six treatments and one follow-up visit.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-09; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-03-26
Trial Details
NCT Number NCT07024550
Lead Sponsor BTL Industries Ltd.
Conditions Binge Eating Behaviour, Binge Eating/Loss of Control Eating, Food Craving
Enrollment 8 participants
Start Date 2025-07-22
Primary Completion 2025-11-04 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-31